These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 28721012)
21. Molecular mechanisms of treadmill therapy on neuromuscular atrophy induced via botulinum toxin A. Tsai SW; Chen HL; Chang YC; Chen CM Neural Plast; 2013; 2013():593271. PubMed ID: 24327926 [TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of a new botulinum toxin type A preparation in mouse gastrocnemius muscle. Na J; Lee E; Kim YJ; Choi MJ; Kim SY; Nam JS; Yun BJ; Kim BJ Toxicon; 2020 Nov; 187():163-170. PubMed ID: 32918927 [TBL] [Abstract][Full Text] [Related]
23. Comparison between neurectomy and botulinum toxin A injection for denervated skeletal muscle. Tsai FC; Hsieh MS; Chou CM J Neurotrauma; 2010 Aug; 27(8):1509-16. PubMed ID: 20528164 [TBL] [Abstract][Full Text] [Related]
24. Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures. Pingel J; Nielsen MS; Lauridsen T; Rix K; Bech M; Alkjaer T; Andersen IT; Nielsen JB; Feidenhansl R Sci Rep; 2017 Nov; 7(1):14746. PubMed ID: 29116170 [TBL] [Abstract][Full Text] [Related]
25. Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin. Meunier FA; Colasante C; Faille L; Gastard M; Molgó J Pflugers Arch; 1996; 431(6 Suppl 2):R297-8. PubMed ID: 8739382 [TBL] [Abstract][Full Text] [Related]
26. Comparative study of biological activity of four botulinum toxin type A preparations in mice. Chung ME; Song DH; Park JH Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819 [TBL] [Abstract][Full Text] [Related]
27. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals. Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439 [TBL] [Abstract][Full Text] [Related]
28. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. Brown M; Nicholson G; Ardila MC; Satorius A; Broide RS; Clarke K; Hunt T; Francis J J Neural Transm (Vienna); 2013 Feb; 120(2):291-8. PubMed ID: 22842675 [TBL] [Abstract][Full Text] [Related]
29. Long-term effects of botulinum toxin on neuromuscular function. Frick CG; Richtsfeld M; Sahani ND; Kaneki M; Blobner M; Martyn JA Anesthesiology; 2007 Jun; 106(6):1139-46. PubMed ID: 17525589 [TBL] [Abstract][Full Text] [Related]
30. Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm. Hott JS; Dalakas MC; Sung C; Hallett M; Youle RJ Neurology; 1998 Feb; 50(2):485-91. PubMed ID: 9484377 [TBL] [Abstract][Full Text] [Related]
31. Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin. Mukund K; Mathewson M; Minamoto V; Ward SR; Subramaniam S; Lieber RL Muscle Nerve; 2014 Nov; 50(5):744-58. PubMed ID: 24536034 [TBL] [Abstract][Full Text] [Related]
32. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats. Ma J; Shen J; Lee CA; Elsaidi GA; Smith TL; Walker FO; Rushing JT; Tan KH; Koman LA; Smith BP J Orthop Res; 2005 Mar; 23(2):302-9. PubMed ID: 15734240 [TBL] [Abstract][Full Text] [Related]
33. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
34. Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy? Dressler D; Bigalke H J Neural Transm (Vienna); 2017 Oct; 124(10):1223-1225. PubMed ID: 28770389 [TBL] [Abstract][Full Text] [Related]
35. Thrombin reduces MuSK and acetylcholine receptor expression along with neuromuscular contact size in vitro. Faraut B; Ravel-Chapuis A; Bonavaud S; Jandrot-Perrus M; Verdière-Sahuqué M; Schaeffer L; Koenig J; Hantaï D Eur J Neurosci; 2004 Apr; 19(8):2099-108. PubMed ID: 15090037 [TBL] [Abstract][Full Text] [Related]
36. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156 [TBL] [Abstract][Full Text] [Related]
37. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Eleopra R; Montecucco C; Devigili G; Lettieri C; Rinaldo S; Verriello L; Pirazzini M; Caccin P; Rossetto O Clin Neurophysiol; 2013 May; 124(5):999-1004. PubMed ID: 23245668 [TBL] [Abstract][Full Text] [Related]
38. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy. Williams SA; Reid S; Elliott C; Shipman P; Valentine J Dev Med Child Neurol; 2013 Sep; 55(9):813-20. PubMed ID: 23789782 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of reconstituted and stored botulinum toxin type A: an electrophysiologic and visual study in the auricular muscle of the rabbit. Jabor MA; Kaushik R; Shayani P; Ruiz-Razura A; Smith BK; Morimoto KW; Cohen BE Plast Reconstr Surg; 2003 Jun; 111(7):2419-26; discussion 2427-31. PubMed ID: 12794491 [TBL] [Abstract][Full Text] [Related]
40. Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections. Minamoto VB; Suzuki KP; Bremner SN; Lieber RL; Ward SR Muscle Nerve; 2015 Oct; 52(4):649-57. PubMed ID: 25598004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]